In This Issue  by unknown
1231Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014
OPTOMETRY AND VISION SCIENCE
Copyright © 2014 American Academy of Optometry
IN THIS ISSUE
IN THIS ISSUE
•	 Therapeutic Priority of  
the PI3k/AKT/mTOR 
Pathway in Small-Cell Lung 
Cancers as Revealed by a 
Comprehensive Genomic 
Analysis
treatment-naïve Japanese patients with stage I–IV SCLC 
(median age 67 years, 98% with smoking history, >50% 
stage I) were evaluated by whole exon sequencing 
and copy number analysis. The analysis showed a 
high prevalence of inactivating mutations in TP53 
and RB1, and MYC amplification. Tumors (36%) also 
harbored genetic mutations in the PI3K/AKT/mTOR 
pathway, which were mutually exclusive. Overall, this 
study suggests that a sequencing-based comprehensive 
analysis could stratify SCLC patients with genetic 
mutations of the PI3K/AKT/mTOR pathway, 
particularly PIK3CA mutations, for currently available 
PI3K inhibitor therapy. (p. 1407)
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This study aimed to dissect the genomic alterations in small-cell 
lung cancer (SCLC) that could be potential therapeutic targets. 
Surgically resected tumors and paired normal tissues of 51 
•	 Canadian Anaplastic 
Lymphoma Kinase 
(CALK) Study: A 
Model for Multicenter 
Standardization and 
Optimization of ALK  
Testing in Lung Cancer
adenocarcinomas with known ALK status (n = 28) 
using locally developed IHC assays for 5A4, ALK-1 
or D5F3 antibodies, and FISH assay based on Vysis’ 
ALK break-apart FISH kit. After optimizing local IHC 
assays using the initial IHC results and assessing the 
standardization with a repeat IHC study, a prospective 
parallel IHC and FISH assessment was performed using 
postvalidation optimized assays on 411 consecutive 
clinical samples. The intraclass correlation coefficients 
for preoptimization IHC results with 5A4 was 0.83 
(which was improved to 0.94 postoptimization), and 0.68 
for FISH scores. The parallel testing of optimized IHC 
and FISH demonstrated 100% sensitivity and specificity 
in IHC against FISH. These findings support a validated 
IHC assay in screening for ALK+ lung cancers. (p. 1255)
The authors in the CALK study set out to optimize and standardize 
ALK detection using immunohistochemistry (IHC) and fluorescence 
in situ hybridization (FISH) assays developed in the laboratory 
across 14 hospitals. Blinded analysis were conducted on lung 
•	 An Evidence-Based 
Determination of Issues 
Affecting Quality of Life 
and Patient-Reported 
Outcomes in Lung Cancer: 
Results of a Survey of 660 
Patients
cohorts, who ranked 20 quality of life issues on a scale 
indicating their importance. The survey revealed that 
quality of life, maintaining independence, ability to 
perform normal activities, ability to sleep, and not 
being fatigued were the top five issues. This indicates 
the importance of global issues related to the impact 
of symptoms on patients, rather than the symptoms 
themselves, demonstrating that PRO measures 
evaluating symptoms only may fail to address patients’ 
needs. In conclusion, the study provided evidence-based 
data that support the content validity of the existing 
Lung Cancer Symptom Scale measures and suggest 
additional items, such as quality of life, maintaining 
independence, and ability to sleep for revision. (p. 1243)
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In response to concerns on the lack of patient input in patient 
reported outcomes (PROs), an anonymous, cross-sectional, 
electronic web-based survey of 660 patients (median age 62 years) 
with lung cancer was conducted to provide content validity for 
measures evaluating quality of life and PROs. It was designed to 
determine which PRO items are most critical in large cancer patient 
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•	 RET Mutation and 
Expression in Small-Cell 
Lung Cancer
of the downstream effects of stable overexpression 
of both wild-type RET and mutant M918T in vitro 
showed activated ERK signaling, MYC expression, 
and increased cell proliferation. These cells also 
demonstrated similar sensitivity to RET tyrosine kinase 
inhibitors vandetabin and ponatinib. mRNA analysis 
indicated a wide variation of RET expression in SCLC 
cells and tumors, which was significantly higher 
than that in lung adenocarcinoma cells (p < 0.05). 
Taken together, the findings suggest that RET could 
represent a new target for tyrosine kinase inhibition in 
a subpopulation of SCLC patients. Further studies in 
validating variable RET protein expression in a larger 
SCLC cohort and including more genomic data from 
metastatic tumors in addition to resected primary tumors 
are warranted. (p. 1316)
Genomic profiling of small-cell lung cancer (SCLC) is hindered 
by restricted access to surgically resected tumors. Using a clinical/
pathologic database of SCLC patients with diagnostic pathologic 
samples (n = 412), the authors sought to quantitate the distribution 
of biopsy specimens available for genomic analysis and determine 
mutations associated with this disease. They demonstrated that 
primary resected tumor tissues only accounted for less than 3% of 
all biopsy specimens of SCLC. By sequencing six tumors (three 
primary and three metastatic), they identified an activating RET 
M918T somatic mutation in a metastatic SCLC tumor. Evaluation 
RESEARCH WATCH
•	 Prognostic and Therapeutic 
Implications of Aromatase 
Expression in Lung 
Adenocarcinomas with 
Egfr Mutations
cell lines were used for analyzing the effects of 
the aromatase inhibitor exemestane, alone and in 
combination with erlotinib. High aromatase expression 
was correlated with poor prognosis for recurrence-free 
survival (p = 0.004) and overall survival (p = 0.003). 
This association was limited to females, never-
smokers, and EGFR-mutated tumors. High aromatase 
expression and EGFR mutation was also associated with 
significant antitumor effects of exemestane, alone and 
in combination with erlotinib. Taken together, aromatase 
could be a potential candidate prognostic factor and 
therapeutic target in patients with EGFR-mutated lung 
adenocarcinomas.
Kohno M, Okamoto T, Suda K, et al. Prognostic and 
therapeutic implications of aromatase expression in lung 
adenocarcinomas with EGFR mutations. Clin Cancer 
Res 2014. doi:10.1158/1078-0432.ccr-13–2683.
The authors were interested in understanding if gender-dependent 
hormones have any role in patients with lung adenocarcinoma with 
no smoking history. They investigated aromatase mRNA expression 
in lung adenocarcinoma and its association with EGFR mutations 
and prognosis postsurgery. Patient tumor samples (n = 110) were 
evaluated for aromatase mRNA expression, whereas EGFR-mutated 
•	 CRIPTO1 Expression in 
EGfR-Mutant Non–Small-
Cell Lung Cancer Elicits 
Intrinsic EGfR-Inhibitor 
Resistance
but not ZEB1. From in vitro and in vivo models as 
well as patient tumors, overexpression of CRIPTO1 
is associated with intrinsic resistance to EGFR-TKI 
in NSCLC harboring EGFR-sensitizing mutations, 
when compared with EGFR-TKI sensitive tumors 
and CRIPTO1 knock-out cells (erlotinib sensitivity 
restored). Targeting EGFR and SRC simultaneously 
resulted in synergistic inhibition of CRIPTO1-positive, 
erlotinib-resistant NSCLC cells in vitro and in vivo. 
Taken together, the findings suggest that the strategy 
of co-targeting EGFR and SRC may address intrinsic 
EGFR-inhibitor resistance in patients with CRIPTO1-
positive and EGFR-mutant NSCLC.
Park K-S, Raffeld M, Moon YW, et al. CRIPTO1 
expression in EGFR-mutant NSCLC elicits 
intrinsic EGFR-inhibitor resistance. J Clin Invest 
2014;124:3003–3015.
Park et al. demonstrated that CRIPTO1, a member of the EGF-
CFC family, activated both ZEB1 that mediates epithelial-to-
mesenchymal transition (EMT), and SRC that stimulates AKT and 
MEK, through miR-205 downregulation in EGFR-TKI resistant 
non–small-cell lung cancer (NSCLC) cells with EGFR mutations. 
miR-205 downregulation was shown to induce erlotinib resistance, 
whereas its overexpression restored erlotinib sensitivity through 
CRIPTO1-mediated ZEB1 and SRC activation. The mechanism 
of CRIPTO1-mediated erlotinib resistance involves the SRC axis 
1233Copyright © 2014 by the International Association for the Study of Lung Cancer
•	 Impact of Lung Cancer 
Screening Results on 
Smoking Cessation
with normal screening findings, major unsuspicious 
abnormality (odds ratio [OR] = 0.811; p < 0.001), stable 
suspicious finding (OR = 0.785; p < 0.001), and new/
changed suspicious finding (OR = 0.663; p < 0.001) 
led to significant reductions in smoking rates. These 
differences lasted up to 5 years after the last screen. The 
authors concluded that smoking cessation is statistically 
associated with abnormalities detected in screening 
and suggested that incorporation of smoking cessation 
efforts into screening program would further reduce 
smoking-related diseases.
Tammemägi MC, Berg CD, Riley TL, et al. Impact 
of lung cancer screening results on smoking cessation. 
JNCI 2014;106. doi:10.1093/jnci/dju084.
In this study of evaluating how Lung Cancer Screening results 
affect smoking cessation, the authors analyzed data from the 
National Lung Screening Trial in current smokers at enrollment 
(n = 15,489), who were not diagnosed with lung cancer during 
the trial. The findings demonstrated that progressively increasing 
number of abnormalities in screening was significantly associated 
with smoking cessation during follow-up (p < 0.0001). Compared 
•	 Economic Evaluations of 
Tobacco Control Mass 
Media Campaigns: A 
Systematic Review
literature found 10 studies that met the inclusion criteria, 
which were then reviewed on the key features and 
quality of the studies. Analyses of cost effectiveness, 
cost utility, or both were reported in these studies, but 
the methods of analysis used were highly variable, 
especially with regards to the types of costs. All in all, 
the review provided evidence of acceptable quality, 
although limited, which suggests that tobacco control 
mass media campaigns are cost-effective in public 
health intervention.
Atusingwize E, Lewis S, Langley, T. Economic 
evaluations of tobacco control mass media campaigns: 
a systematic review. Tob Control 2014. doi:10.1136/
tobaccocontrol-2014–051579.
Atusingwize et al. conducted a systematic and comprehensive 
review on published economic evaluations of tobacco control mass 
media campaigns to critically assess if the cost and benefits of this 
intervention are justified. An electronic search of databases and 
•	 It is Time to Regulate 
Carcinogenic Tobacco-
Specific Nitrosamines in 
Cigarette Tobacco
regulation of NNK and NNN in cigarette tobacco as a 
step toward cancer prevention. The levels of NNK and 
NNN in tobacco directly reflect their levels in cigarette 
smoke, both of which are affected by choice of tobacco 
blend, agricultural conditions, and processing methods. 
Products in the United States are shown to have some 
of the highest NNK and NNN levels. Hecht urged that 
regulation should be in place to generate cigarettes 
containing ≤100 ppb NNK and NNN. This would in 
turn reduce these carcinogens by approximately 15–20 
fold in the smoke of popular cigarettes in the United 
States and globally.
Hecht SS. It is time to regulate carcinogenic tobacco-
specific nitrosamines in cigarette tobacco. Cancer Prev 
Res 2014;7:639–647.
Nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and N′-nitrosonornicotine (NNN) are strong carcinogens 
to humans according to the International Agency for Research on 
Cancer. This commentary by Stephen Hecht calls for immediate 
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•	 E-Cigarette Online Sales 
Rising, Survey Says
A study led by Shu-Hong Zhu, published in the 
Journal of Tobacco Control, reported results of the first 
comprehensive survey of e-cigarettes for sale online 
from 2012 to 2014. An average of 10 new e-cigarette 
brands entered the online market each month. Currently, 
there are 466 e-cigarette brands online with more than 
7700 flavors, some of which, like candy flavors, could 
appeal to children. Traditional cigarettes, in contrast 
to e-cigarettes, are only allowed to be sold in tobacco 
and menthol flavors in the United States. A shift 
in the marketing of e-cigarettes was also observed, 
where newer brands provide customizable e-cigarettes 
that have no resemblance to traditional cigarettes. 
The authors support the proposed regulations on 
e-cigarettes by the FDA with the main goal of reducing 
smoking prevalence, but are cautioned of unintended 
consequences as a result of excessively stringent rules.
Photo credit: Pictofigo | Wikimedia Commons | 
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Reid et al. presented the results of their study on 
microRNA (miR) replacement as a therapeutic option 
for malignant pleural mesothelioma (MPM) at the WIN 
Symposium in Paris, France. They found a consistent 
downregulation of the miR-15/16 family in all MPM 
tumors (60 archival formalin-fixed paraffin-embedded 
blocks) and cell lines examined when compared with the 
normal counterparts: expression of miR-16 by 12-fold, 
miR-15a and miR-15b by 7- and 4.7-fold, respectively, 
and miR-195 by 14-fold. Transfection of synthetic 
mimics of miR-16, miR-15a, or miR-15b to restore 
their levels resulted in significant growth inhibition 
of MPM cell lines versus normal cells, particularly 
miR-16. Targeted delivery of the mimics in vivo was 
achieved by intravenous administration of minicells 
(EDVs) developed from bacterial asymmetric cell 
division, which target tumor concurrently by passive 
accumulation at leaky vasculature and EGFR-specific 
antibody (due to frequent EGFR overexpression 
in MPM). This approach led to significant tumor 
growth inhibition (p < 0.01). It was also observed that 
mimics with novel sequences based on the miR-15/16 
family consensus elicited enhanced antitumor activity 
compared with native miR-16 in vitro and in vivo. 
These findings provided solid support for the use of 
miR mimics as a novel treatment for MPM. A phase 0/1 
trial is underway and aims to assess the biodistribution, 
safety, and optimal dose of novel miR-16-based mimics 
packaged in minicells for patients with recurrent MPM 
or non–small-cell lung cancer.
•	 Win Symposium 2014: 
Targeted Delivery of 
a Microrna Mimic as 
a Novel Approach to 
Therapy for Malignant 
Pleural Mesothelioma
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•	 Policy, The Law, and 
Tobacco Control
this matter in Indonesia, Thailand, Australia, the United 
States, the Philippines, and Uruguay (see the link 
below). A table best summarizes the information:
http://www.washingtonpost.com/business/
more-countries-adding-graphic-warnings-to-
smokes/2014/06/27/45264be0-fdbc-11e3-beb6-
9c0e896dbcd8_story.html
For information on product labeling in your country 
check out the Tobacco Labelling Resource Centre Web 
site at: http://www.tobaccolabels.ca/
The Web site is hosted by the University of Waterloo 
in Ontario, Canada, and is supported by the Framework 
Convention Alliance and the International Union 
Against Tuberculosis and Lung Disease as a resource for 
promoting accurate labeling of tobacco products.
A January review article in the New England Journal 
of Medicine (http://www.nejm.org/doi/full/10.1056/
NEJMra1308383) discusses tobacco’s global effect, with 
particular emphasis on the risk reduction of smoking 
cessation and on the positive effect of taxing tobacco 
(Jha and Peto, NEJM 2014;370:60–68). The conclusions 
were pointed and clear and accompanied by memorable 
graphics highlighting the importance of excise taxes on 
cigarette consumption. Six notable findings from the 
review are listed below:
1. The benefit of smoking cessation includes higher 
life expectancy: cessation before 30, 40, and 50 
years of age confers approximately 10, 9, and 6 
years of life expectancy, respectively.
2. A large increase in inflation-adjusted cigarette price is 
the key component of any realistic strategy to reduce 
smoking rates substantially in the next decade.
3. There are two types of tobacco tax (excise which 
is weight-based) and ad valorem (based on man-
ufacturer-defined price, susceptible to industry 
manipulation).
4. A low specific excise tax on tobacco is the main rea-
son that cigarettes are approximately 70% cheaper 
(even after adjustment for purchasing power) in many 
low-income countries than in high-income countries.
5. Tripling inflation-adjusted specific excise taxes on 
tobacco would approximately double the average 
price of cigarettes (and more than double prices of 
cheaper brands), which would reduce consumption 
by about one-third.
First things first, Big Tobacco. The Sydney Morning Herald 
reported on July 2 of a first-step legal win for Australia in its battle 
with Philip Morris Asia (PMA) over the plain packaging legislation 
passed in 2011 by the Australian Parliament (see link below). The 
report summarizes a decision by the Permanent Court of Arbitration 
(PCA) (an international dispute resolution organization based in 
The Hague), which will have a significant impact upon the ease 
with which PMA may challenge the Tobacco Plain Packaging Act 
2011. Essentially, PMA owns 100% of the shares of Philip Morris 
Australia (PM Australia), a position which could permit PMA to 
challenge the Act under a trade agreement between Australia and 
Hong Kong (PMA is incorporated in Hong Kong). The Australian 
Government has argued that PMA’s ownership of PM Australia does 
not fall under this trade agreement as PMA only acquired these 
shares after the implementation of plain packing was announced. 
The PCA has found in favor of the Australian government, allowing 
Australia to challenge PMA’s right to contest the plain packaging 
laws, finding that PMA only bought the Australian shares to 
do so. The report contains a link to the McCabe Centre (www.
mccabecentre.org), an Australian-based center for “Law and 
Cancer,” which provides a nice summary of the argument for the 
non-lawyers among us. It gets a little technical but essentially the 
Australian government made procedural objections to PMA’s case 
(before any consideration of merit of the claim), the objections 
had potential to dispose of PMA’s claims (or seriously impede 
them) and led in the end to the “bifurcation” of the proceedings. 
That is procedural objections in the case will be heard in a separate 
preliminary phase without too strong a focus on the merits of the 
case. The McCabe Centre Web site also contains a link to the PCA’s 
procedural order with the decision given on the last page. This is 
a fascinating display of the intellectual gamesmanship required to 
engage in and win these legal battles (and full confirmation of the 
choice of a medical career over a legal one) (http://www.smh.com.
au/national/australia-wins-first-battle-in-plain-packaging-trade-
dispute-20140702-zst8d.html).
Other policy moves toward tobacco control include the 
introduction of mandatory graphic health warnings on cigarette 
packs. Associated Press (through the Washington Post) reports on 
Country Law, % pack covered Timing
Indonesia 40% June 24, 2014
Thailand 85% (increase from 55%) September 2014
Australia 75% front, 90% back 2012
United States 0% N/A
Philippines 50% Pending
Uruguay 80% 2010
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